智通财经APP讯，陇神戎发(300534.SZ)发布公告，公司控股子公司甘肃普安制药股份有限公司(以下简称“普安制药”)于近日收到国家药品监督管理局签发的《药品上市申请不予批准通知书》，该药品为：“布瑞哌唑口溶膜”。本次不予批准的理由：本品药学注册核查结论为不通过。根据《药品注册管理办法》第九十二条第二款第(七)项的规定，不予批准。该药品上市申请未获批准不会对公司当期业绩产生重大影响。
智通财经APP讯，陇神戎发(300534.SZ)发布公告，公司控股子公司甘肃普安制药股份有限公司(以下简称“普安制药”)于近日收到国家药品监督管理局签发的《药品上市申请不予批准通知书》，该药品为：“布瑞哌唑口溶膜”。本次不予批准的理由：本品药学注册核查结论为不通过。根据《药品注册管理办法》第九十二条第二款第(七)项的规定，不予批准。该药品上市申请未获批准不会对公司当期业绩产生重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.